Literature DB >> 10379235

Experimental infections with Actinobacillus pleuropneumoniae in pigs--I. Comparison of five different parenteral antibiotic treatments.

P Wallgren1, T Segall, A Pedersen Mörner, A Gunnarsson.   

Abstract

SPF pigs aged 10 weeks were infected intranasally with Actinobacillus pleuropneumoniae serotype 2. After the onset of clinical symptoms of respiratory disease, which occurred 20 h post-infection, parenteral treatment with ceftiofur, danofloxacin, enrofloxacin, penicillin or tiamulin was initiated (n = 8 per group). Untreated groups, of which one was infected, served as controls. The uninfected control group did not show any signs of disease, while the infected control group was severely affected by the infection and also expressed a decreased weight gain following the challenge. Based on clinical signs, the magnitude of pathological lesions in the respiratory tract found at necropsy performed 17 days post-infection and the number of reisolates of A. pleuropneumoniae made at necropsy, treatments with the quinolones (danofloxacin and enrofloxacin) and the cephalosporine (ceftiofur) were superior to those with penicillin and tiamulin. The latter groups also developed antibodies to A. pleuropneumoniae to a larger extent. Some of the pigs treated with ceftiofur and danofloxacin developed antibodies to A. pleuropneumoniae, and the microbe was reisolated from approximately 50% of these animals. In contrast, pigs treated with enrofloxacin did not develop antibodies to A. pleuropneumoniae, and the challenge strain was not found at necropsy. The performance with respect to daily weight gain and feed conversion corresponded well with the clinical signs developed and the findings made at necropsy. The decreased growth recorded during the acute phase of the disease was, to a large extent, caused by a reduced feed intake.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379235

Source DB:  PubMed          Journal:  Zentralbl Veterinarmed B        ISSN: 0514-7166


  8 in total

1.  Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.

Authors:  H Yoshimura; M Takagi; M Ishimura; Y S Endoh
Journal:  Vet Res Commun       Date:  2002-01       Impact factor: 2.459

2.  Field experience with two different vaccination strategies aiming to control infections with Actinobacillus pleuropneumoniae in a fattening pig herd.

Authors:  Marie Sjölund; Per Wallgren
Journal:  Acta Vet Scand       Date:  2010-03-25       Impact factor: 1.695

3.  Viral Metagenomic Analysis Displays the Co-Infection Situation in Healthy and PMWS Affected Pigs.

Authors:  Anne-Lie Blomström; Caroline Fossum; Per Wallgren; Mikael Berg
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

4.  Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Jincheng Xiong; Kun Li; Saeed Ahmed; Liping Hong; Pin Chen; Qigai He; Jiyue Cao
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

5.  Efficacy of a one-shot marbofloxacin treatment on acute pleuropneumonia after experimental aerosol inoculation of nursery pigs.

Authors:  Doris Hoeltig; Judith Rohde; Birgit Brunner; Klaus Hellmann; Erik Grandemange; Karl-Heinz Waldmann
Journal:  Porcine Health Manag       Date:  2018-06-22

6.  Exudative epidermitis and porcine circovirus-2 infection in a Swedish SPF-herd.

Authors:  Eva Wattrang; Francis McNeilly; Gordon M Allan; Christina Greko; Caroline Fossum; Per Wallgren
Journal:  Vet Microbiol       Date:  2002-05-24       Impact factor: 3.293

7.  Exposure to benzylpenicillin after different dosage regimens in growing pigs.

Authors:  Marie Sjölund; Carl Ekstrand; Per Wallgren; Ulf Bondesson; Märit Pringle; Björn Bengtsson
Journal:  Acta Vet Scand       Date:  2020-09-17       Impact factor: 1.695

8.  Characterisation of the Virome of Tonsils from Conventional Pigs and from Specific Pathogen-Free Pigs.

Authors:  Anne-Lie Blomström; Xingyu Ye; Caroline Fossum; Per Wallgren; Mikael Berg
Journal:  Viruses       Date:  2018-07-20       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.